SEC Filing Document

Company: Ambitious Entertainment, Inc.
Ticker: 
CIK: 1900851
Filing Type: DRS
Document Type: DRS
Date Filed: 2025-07-17
Accession Number: 0001493152-25-011282
Exchange: 
SIC Code: 7812
SIC Description: Services-Motion Picture & Video Tape Production
URL: https://www.sec.gov/Archives/edgar/data/1900851/000149315225011282/filename1.htm

Chunk 6 of 56
Word Count: 1486
Character Count: 9258

Document Content:

proceeds from this offering. do not anticipate that we will pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock. ● Anti-takeover effects of certain provisions of Nevada state law may hinder a potential takeover of us. ● For as long as we are an emerging growth company, we will not be required to comply with certain requirements that apply to other public companies. are a “smaller reporting company” and, even if we no longer qualify as an emerging growth company, we may still be subject to reduced reporting requirements. ● Sales of a substantial number of shares of our common stock following this offering may adversely affect the market price of our common stock and the issuance of additional shares will dilute all other stockholders. Implications of Being a Controlled Company

of ______, 2025, our Co-President and Interim Chief Executive Officer, Mr. Kirk Shaw, beneficially owned [●] shares of our
common stock, representing [●]% of our issued and outstanding shares of our common stock. Upon completion of this offering, Mr.
Shaw will hold approximately [●]% (or [●]% if the underwriters’ overallotment option is exercised in full) of our issued
and outstanding common stock. Therefore, following the completion of this offering will continue to be, a “controlled company”
as defined under Section 303A of the NYSE Listed Company Manual. Mr. Shaw will continue to significantly influence the election of our directors
and the outcome of corporate actions requiring stockholder approval, such as: (i) a merger or a sale of our company, (ii) a sale of all
or substantially all of our assets, and (iii) amendments to our articles of incorporation and bylaws.

Implications
of Being an Emerging Growth Company

are an “emerging growth company” as defined in Section 2(a) of the Securities Act of 1933, as amended (the Securities Act).
For as long as we are an emerging growth company, we will not be required to:

●	provide
an auditor’s attestation report on management’s assessment of the effectiveness
of our system of internal control over financial reporting pursuant to Section 404(b) of
the Sarbanes-Oxley Act of 2002 (the “Sarbanes Oxley Act”);

●	provide
more than two years of audited financial statements and related management’s discussion
and analysis of financial condition and results of operations;

●	comply
with any new requirements adopted by the Public Company Accounting Oversight Board (the “PCAOB”)
requiring mandatory audit firm rotation or a supplement to the auditor’s report in
which the auditor would be required to provide additional information about the audit and
the financial statements of the issuer;

●	provide
certain disclosure regarding executive compensation required of larger public companies or
hold stockholder advisory votes on the executive compensation required by the Dodd-Frank
Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), or

●	obtain
stockholder approval of any golden parachute payments not previously approved.

will cease to be an emerging growth company upon the earliest of the following:

●	the
last day of the fiscal year in which we have $1.235 billion or more in total annual gross
revenues;

●	the
date on which we become a “large accelerated filer” (the fiscal year-end on which
the total market value of our common equity securities held by non-affiliates is $700 million
or more as of June 30);

●	the
date on which we issue more than $1.0 billion of non-convertible debt over a three-year period,

●	the
last day of the fiscal year following the fifth anniversary of our initial public offering.

have elected to take advantage of certain of the reduced disclosure obligations in this prospectus, and may elect to take advantage of
other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different
than you might receive from other public reporting companies.

addition, “emerging growth company” may take advantage of the extended transition period provided in Section 7(a)(2)(B) of
the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can
delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

Implications
of Being a Smaller Reporting Company

are a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage
of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We
will remain a smaller reporting company until the last day of any fiscal year for so long as either: (i) the market value of our shares
of common stock held by non-affiliates does not equal or exceed $250 million as of the prior June 30; or (ii) our annual revenues did
not equal or exceed $100 million during such completed fiscal year. To the extent we take advantage of such reduced disclosure obligations,
it may also make comparison of our financial statements with other public companies difficult or impossible.

Corporate
Information

Our
mailing address is 530 S. 8th Street, Las Vegas, Nevada 89101. Our telephone number is _____. The address of our website is www.ambitious.tv.
The inclusion of our website address in this prospectus does not include or incorporate by reference the information on our website into
this prospectus.

The
Offering

The
following is a summary of certain terms of this offering.

Securities
offered by us: [●]
shares of common stock, par value $0.001 per share.

Initial
public offering price: $[●]
per share, which is the mid-point of the estimated initial public offering price range set forth on the cover of this prospectus.

Number
of shares of common stock outstanding before the offering: [●]
shares.

Number
of shares of common stock outstanding after the offering (1): [●]
shares.

Overallotment
option: We
have granted the underwriters an option exercisable in whole or in part and from time to time for a period of up to [●] days
from the date of this prospectus to purchase from us up to   an additional [●] shares of our common stock at the
initial public offering price per share, less underwriting discounts and commissions, solely to cover over-allotments, if any.

Use
of proceeds: We
estimate that we will receive net proceeds of approximately $[●] million, assuming an initial public offering price of $[●]
per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the underwriting discounts
and commissions and estimated offering expenses payable by us.

[Although
we have not yet determined with certainty the manner in which we will allocate the net proceeds of this offering], we expect to use
the net proceeds from this offering for [__], offering expenses, and other general corporate purposes. We may also use a portion
of the proceeds from this offering for [________]. We have not allocated specific amounts of net proceeds for any of these purposes.
See “Use of Proceeds”.

Risk
factors: An
investment in our securities involves a high degree of risk. See “Risk Factors” beginning on page 13 of this prospectus
and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding to
invest in shares of our common stock.

Lock-up: We
and our directors, officers and certain of our stockholders have agreed not to offer for sale, issue, sell, contract to sell, pledge
or otherwise dispose of any shares of our common stock or securities convertible into or exercisable for shares of our common stock
for a period of [●] days after the date of this prospectus. See “Underwriting”.

Representative’s
Warrants: We
have agreed to issue to the representative of the underwriters or its designees at the closing
of this offering, warrants to purchase the number of shares of our common stock equal to
[●]% of the aggregate number of shares sold in this offering, including any shares
of our common stock sold pursuant to the underwriters’ over-allotment option (the “Representative’s
Warrants”). The Representative’s Warrants will be exercisable at any time and
from time to time, in whole or in part, during the four-and-a-half-year period commencing
six months after the commencement of sales in this offering. The exercise price of the Representative’s
Warrants will equal [●]% of the initial public offering price per share, subject to
adjustments. See “Underwriting”.

NYSE
Trading Symbol: We
intend to apply have the shares of our common stock offered hereby listed on the NYSE American under the symbol “___”.
No assurance can be given that our application will be approved. We will not proceed with this offering in the event shares of our
common stock are not approved for listing on the NYSE American.

(1)	The
number of shares that will be outstanding after this offering is based on [●] shares
of common stock outstanding as of _______, 2025, but excludes:

shares of our common stock reserved for future issuance under our equity compensation plans;